PMID- 22502695 OWN - NLM STAT- MEDLINE DCOM- 20120814 LR - 20190606 IS - 2476-762X (Electronic) IS - 1513-7368 (Linking) VI - 13 IP - 1 DP - 2012 TI - Efficacy of primed in situ labelling in determination of HER-2 gene amplification and CEN-17 status in breast cancer tissue. PG - 329-37 AB - Considerable attention has been given to the accuracy of HER-2 testing and the correlation between the results of different testing methods. This interest reflects the growing importance of HER-2 status in the management of patients with breast cancer. In this study the detection of HER-2 gene and centromere 17 status was evaluated using dual-colour primed in situ labelling (PRINS) in comparison with fluorescence in situ hybridization (FISH). These two methods were evaluated on a series of 27 formalin fixed paraffin embedded breast carcinoma tumours, previously tested for protein overexpression by HercepTest (grouped into Hercep 1+/0, 2+ and 3+). HER-2 gene amplification (ratio >/= 2.2) by PRINS was found in 3:3, 6:21 and 0:3 in IHC 3+, 2+ and 1+/0 cases, respectively. Comparing FISH and IHC (immunohistochemistry), showed the same results as for PRINS and IHC. Chromosome 17 aneusomy was found in 10 of 21 IHC 2+ cases (47.6%), of which 1 (10%) showed hypodisomy (chromosome 17 copy number per cell /= 3.76). The overall concordance of detection of HER-2 gene amplification by FISH and PRINS was 100% (27:27). Furthermore, both the level of HER-2 amplification and copy number of CEN17 analysis results correlated well between the two methods. In conclusion, PRINS is a reliable, reproducible technique and in our opinion can be used as an additional test to determine HER-2 status in breast tumours. FAU - Salimi, Mahdieh AU - Salimi M AD - Department of Medical Genetics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran. FAU - Mozdarani, Hossein AU - Mozdarani H FAU - Majidzadeh-A, Keivan AU - Majidzadeh-A K LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Thailand TA - Asian Pac J Cancer Prev JT - Asian Pacific journal of cancer prevention : APJCP JID - 101130625 RN - EC 2.7.10.1 (Receptor, ErbB-2) SB - IM MH - Breast Neoplasms/*genetics/metabolism/pathology MH - Centrosome MH - *Chromosome Aberrations MH - Chromosomes, Human, Pair 17/*genetics MH - Female MH - *Gene Amplification MH - Gene Expression Regulation, Neoplastic MH - Humans MH - Immunoenzyme Techniques MH - In Situ Hybridization, Fluorescence MH - Paraffin Embedding MH - Primed In Situ Labeling/*methods/statistics & numerical data MH - Prognosis MH - Receptor, ErbB-2/*genetics/metabolism EDAT- 2012/04/17 06:00 MHDA- 2012/08/15 06:00 CRDT- 2012/04/17 06:00 PHST- 2012/04/17 06:00 [entrez] PHST- 2012/04/17 06:00 [pubmed] PHST- 2012/08/15 06:00 [medline] AID - 10.7314/apjcp.2012.13.1.329 [doi] PST - ppublish SO - Asian Pac J Cancer Prev. 2012;13(1):329-37. doi: 10.7314/apjcp.2012.13.1.329.